Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Journal Abstract

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Publication Date: 2024 May 30

Full Text Sources

Authors

Martin S Maron; Ahmad Masri; Michael E Nassif; Roberto Barriales-Villa; Michael Arad; Nuno Cardim; Lubna Choudhury; Brian Claggett; Caroline J Coats; Hans-Dirk Düngen; Pablo Garcia-Pavia; Albert A Hagège; James L Januzzi; Matthew M Y Lee; Gregory D Lewis; Chang-Sheng Ma; Michelle Michels; Iacopo Olivotto; Artur Oreziak; Anjali T Owens; John A Spertus; Scott D Solomon; Jacob Tfelt-Hansen; Marion van Sinttruije; Josef Veselka; Hugh Watkins; Daniel L Jacoby; Stephen B Heitner; Stuart Kupfer; Fady I Malik; Lisa Meng; Amy Wohltman; Theodore P Abraham

Abstract

OBJECTIVE

One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction. Aficamten is an oral selective cardiac myosin inhibitor that reduces left ventricular outflow tract gradients by mitigating cardiac hypercontractility.

Source

The New England journal of medicine

Pub Types(s)

Journal Article

Language

English

PubMed ID

38739079